Glycosylation diseases: Quo vadis?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
About 250 to 500 glycogenes (genes that are directly involved in glycan assembly) are in the human genome representing about 1–2% of the total genome. Over 40 human congenital diseases associated with glycogene mutations have been described to date. It is almost certain that the causative glycogene mutations for many more congenital diseases remain to be discovered. Some glycogenes are involved in the synthesis of only a specific protein and/or a specific class of glycan whereas others play a role in the biosynthesis of more than one glycan class. Mutations in the latter type of glycogene result in complex clinical phenotypes that present difficult diagnostic problems to the clinician. In order to understand in biochemical terms the clinical signs and symptoms of a patient with a glycogene mutation, one must understand how the glycogene works. That requires, first of all, determination of the target protein or proteins of the glycogene followed by an understanding of the role, if any, of the glycogene-dependent glycan in the functions of the protein. Many glycogenes act on thousands of glycoproteins. There are unfortunately no general methods to identify all the potentially large number of glycogene target proteins and which of these proteins are responsible for the mutant phenotypes. Whereas biochemical methods have been highly successful in the discovery of glycogenes responsible for many congenital diseases, it has more recently been necessary to use other methods such as homozygosity mapping. Accurate diagnosis of many recently discovered diseases has become difficult and new diagnostic procedures must be developed. Last but not least is the lack of effective treatment for most of these children and of animal models that can be used to test new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suppression of tumor growth and metastasis in Mgat5-deficient mice
Granovsky, M., Fata, J., Pawling, J., Muller, W. J., Khokha, R., & Dennis, J. W. (2000) · Nature Medicine · doi:10.1038/73163 · Cited by 569 · cited 6×
“(i) GlcNAcTV has been shown to stimulate tumor metastasis in mice [77].”
BackgroundInfluentialSchachter, H. (1986) · Biochemistry and Cell Biology · doi:10.1139/o86-026 · Cited by 526
Self-citationWang, X., Inoue, S., Gu, J., Miyoshi, E., Noda, K., Li, W., Mizuno-Horikawa, Y., Nakano, M., Asahi, M., Takahashi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507375102 · Cited by 476
Niehues, R., Hasilik, M., Alton, G., Körner, C., Schiebe-Sukumar, M., Koch, H. G., Zimmer, K. P., Wu, R., Harms, E., Reiter, K., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2350 · Cited by 422
Self-citationSimpson, M. A., Cross, H., Proukakis, C., Priestman, D. A., Neville, D. C. A., Reinkensmeier, G., Wang, H., Wiznitzer, M., Gurtz, K., Verganelaki, A., et al. (2004) · Nature Genetics · doi:10.1038/ng1460 · Cited by 389
Reitman, M. L., Varki, A., & Kornfeld, S. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110189 · Cited by 321 · cited 2×
“Although patients with congenital abnormalities in glycan assembly (glycan biosynthesis and binding) are relatively rare, well over 40 human congenital diseases associated with glycogene mutations have been described to date: 16 Type I Congenital Disorders of Glycosylation (CDG-Ia to CDG-Ip) [7–14], 8 Type II CDGs (CD…”
BackgroundHandbook of Glycosyltransferases and Related Genes
(2014) · doi:10.1007/978-4-431-54240-7 · Cited by 318
Aberrant Glycosylation of E-cadherin Enhances Cell-Cell Binding to Suppress Metastasis
Yoshimura, M., Ihara, Y., Matsuzawa, Y., & Taniguchi, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13811 · Cited by 209 · cited 4×
“anti-metastatic effect thatmay be due, at least in part, to altered N-glycan structures on E-cadherin [76,78].”
BackgroundInfluentialThiele, H., Sakano, M., Kitagawa, H., Sugahara, K., Rajab, A., Höhne, W., Ritter, H., Leschik, G., Nürnberg, P., & Mundlos, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400334101 · Cited by 190
Panneerselvam, K., & Freeze, H. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118570 · Cited by 146
Self-citation
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
Bennett, E. P., Mandel, U., Clausen, H., Gerken, T. A., Fritz, T. A., & Tabak, L. A. (2012) · Glycobiology · doi:10.1093/glycob/cwr182 · Cited by 876
Hart, G. W., & Copeland, R. J. (2010) · Cell · doi:10.1016/j.cell.2010.11.008 · Cited by 643
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics
Thomas, D., Rathinavel, A. K., & Radhakrishnan, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188464 · Cited by 372
Sulfation of Glycosaminoglycans and Its Implications in Human Health and Disorders
Soares da Costa, D., Reis, R. L., & Pashkuleva, I. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044610 · Cited by 324
Metadata
- Authors
- Schachter, H., & Freeze, H. H.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 1792
- Issue
- 9
- Pages
- 925-930
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W2096557906
- Cited by
- 111
- References
- 13
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycosylation diseases: Quo vadis? https://app.cochat.ai/papers/10.1016/j.bbadis.2008.11.002
- The paper
- Schachter, H., & Freeze, H. H. (2009). Glycosylation diseases: Quo vadis? Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2008.11.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.